PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal™ (“Reveal”), can now be used with liquid-based cytology samples (ThinPrep®). The data will be presented in a poster at the upcoming 86th Annual Meeting of the American Thyroid Association taking place from September 21-25, 2016 at the Sheraton Denver Downtown Hotel in Denver, Colorado.
Data highlighting the utility of RosettaGX Reveal with ThinPrep samples will be available for viewing as follows:
| Poster Title: |
“Analytical Validation of a microRNA-based Diagnostic Assay for Using Liquid-Based Cytology Samples” |
|
| Poster Number: | Short Call Poster 52 | |
| Date/Time: | September 23, 2016 from 9:30 a.m. – 5:30 p.m. | |
| Location: | Exhibit Hall | |
| Presenters: | Dganit Bar, PhD, Chief Scientific Officer, Rosetta Genomics | |
| Nicole Massol, MD, Director of Cytopathology, University of Arkansas Medical Sciences | ||
| Eti Meiri, PhD, Vice President Research—Diagnostics, Rosetta Genomics | ||
ThinPrep® is a registered trademark of Hologic, Inc.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta’s microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160914005727/en/
